Neuroscience — Neural Data Search

Design summary

To test how tau 353-369 sequence variants alter cross-seeding you should (1) make a focused panel of point and PTM-mimic mutants across 353-369, (2) generate defined seeds (recombinant fibrils or brain-derived seeds), (3) measure cross-seeding to WT full-length and repeat-domain tau using orthogonal assays (ThT kinetics, RT-QuIC/PMCA or biosensor cell seeding, capture and seeded aggregation assays), and (4) characterize structures and toxic species by EM, limited proteolysis/DEER and biochemical fractionation. Each step separates seeding potency from templating specificity and structure. Experimental rationale and assay choices are supported by prior seeding and tau peptide work (examples cited below).

Key evidence: seeding assays and capture methods are sensitive to AD-derived and recombinant seeds Two simple tau seeding assays and that small soluble oligomers drive seeding/cross-seeding more than long fibrils Oligomers drive seeding

Designing experiments to test tau 353-369 mutants in cross-seeding

This document gives a practical, evidence-based experimental plan (constructs, assays, controls, readouts, and decision rules), with visual experimental matrices and recommended structural/biochemical followups to dissect whether substitutions in tau residues 353-369 alter seeding potency, templating specificity, and fibril architecture during cross-seeding.

Why residues 353-369 matter

Residues ~353-369 are within the R4/CTE region adjacent to the microtubule binding repeats and the core of multiple disease-derived fibril structures; small peptide motifs and local mutations can alter water structuring, packing and in-register stacking—properties that determine seeding competence and templating capacity Water directed pinning PNAS

Overall experimental logic

1. Generate a focused mutant panel spanning 353-369: conservative (Ala), disruptive (Pro), charge swaps (K->E, E->K), acetylation mimics (K->Q), phosphomimics (S/T->E), and deletions/truncations. Rationale: separate effects on intrinsic aggregation propensity from effects on cross-seeding specificity (see examples where PTM mimics alter aggregation and toxicity) K274Q acetylation mimic study.
2. Make recombinant monomeric WT full-length human tau and the mutant proteins, and prepare seeds: (A) recombinant fibrils assembled under well-characterized conditions, (B) seeded amplifications using AD brain homogenate or AD-derived seeds to produce disease-like cores (per serial amplification approach), and (C) sonicated versus non-sonicated preparations to test oligomer vs fibril contributions because sonication generates toxic oligomers (avoid misinterpreting long fibrils as active agents) Serial amplification and disease like filaments and note that sonication creates small oligomers that may be the active seeding species Oligomers drive seeding.
3. Test cross-seeding in orthogonal assays: biochemical Thioflavin T kinetics, RT-QuIC/PMCA where available, the membrane capture + seeded aggregation assays validated for sensitivity to AD brain seeding, and a cellular biosensor assay (tau RD FRET or tau151-391 aggregation readouts) to measure templated aggregation and intracellular seeding (capture assay and seeded cell aggregation were validated and correlate to phospho-tau and Braak stage) Two tau seeding assays.

Concrete experimental pipeline and timeline (8 weeks for initial screen)

Assay details and decision rules

• ThT aggregation kinetics — measure lag time, growth rate, and final amplitude for seed+m to quantify seeding potency; run seeded and unseeded controls and match monomer concentrations to avoid concentration-driven artifacts Tau amyloid model challenges review.
• RT-QuIC/PMCA-style amplification or ThT-based seeded amplification — gives ultrasensitive readout of seeding potency; use as orthogonal confirmation of ThT results and to amplify low-potency seeds (serial amplification can generate more disease-like cores) Serial amplification study.
• Capture assay and seeded cell aggregation — validated, low-cost assays to quantify seeding from brain regions and tissue; use HEK293 biosensor cells expressing tau RD FRET or HA-tau151-391 to measure intracellular templating (validated vs human AD tissue) Capture and seeded cell assays.
• Structural checks — negative stain TEM and AFM to inspect morphology; limited proteolysis + mass spec to compare core protections; DEER or cryo-EM for top candidates (DEER can evaluate packing order and supramolecular alignment for fibrils) DEER packing assay for fibrils.

Controls and important technical caveats

• Always include a no-seed negative control and a positive seed control (e.g., AD-derived seed or a previously validated recombinant seed).
• Match monomer concentrations across conditions and measure free monomer after assembly to avoid misinterpreting concentration effects as sequence effects (see in vitro model caveats) In vitro model cautions.
• Characterize seed composition (oligomer vs fibril) because sonication can create seeding-competent oligomers; if your seeded activity correlates with oligomer content, interpret in light of oligomer-dominant seeding models Oligomer seeding evidence.
• Use orthogonal readouts (biochemical, cell-based, structural) before concluding that a mutant alters cross-seeding specificity.

Suggested initial mutant panel (example)

• Ala scan: 353A, 354A, 355A ... 369A (or grouped A mutations every 2 residues to keep panel smaller).
• Charge swap: E->K and K->E at any native charged residues in 353-369 to test electrostatic steering.
• PTM mimics: K->Q (acetylation mimic), S/T->E (phosphomimic).
• Insertion of Pro at two positions to disrupt local beta propensity.

Planned output metrics and statistical decision rules

• Primary seeding potency: fold change in ThT initial slope and RT-QuIC end-point t50 relative to WT seed+WT monomer. Significant effect defined as >2-fold change + p<0.01 across 3 independent seed preps (ANOVA + post-hoc).
• Templating specificity: whether mutant seed converts WT monomer to a biochemical/structural species distinct from WT seed; determined by protease footprint pattern, EM morphology, and DEER-derived packing parameter differences (require reproducible, orthogonal differences in at least 2 structural assays).
• Toxicity correlation: use cell viability or neurite integrity assays in primary neurons; test whether variants that increase seeding also increase toxicity.

Example visual experimental matrix (interactive figure)

Legend: rows are seeding pair types and columns are orthogonal assays; heat intensity represents recommended emphasis for initial screen (higher = primary readout).

How to interpret possible outcomes

• Mutant seeds show increased seeding of WT monomer: indicates the mutant stabilizes a template conformation that efficiently templates WT tau; follow up with structural mapping (protease footprint, DEER/cryo-EM) to identify altered core packing (see serial amplification work showing mutations can yield AD-like folds) Serial amplification evidence.
• Mutant seeds show reduced seeding: could mean the substitution disrupts the critical packing motif or prevents formation of seeding-competent oligomers; structural and solubility profiling will distinguish these mechanisms.
• Divergent structural cores despite similar seeding potency: indicates the mutation biases the assembly pathway to an alternative conformer with comparable activity; this may underlie strain-like behavior and requires cryo-EM/DEER mapping.

Key literature to consult (selected)

• Two tau seeding assays
• Oligomer seeding study
• ISAD1 inhibits PHF6 aggregation
• SORL1 promotes tau seeding
• Tau amyloid model review

Limitations and potential blindspots

• In vitro recombinant seeds may not recapitulate PTM patterns or cofactor content of brain-derived seeds; amplified seeds using patient material reduce but do not eliminate these differences Seed amplification caveats.
• Cell-based seeding depends on uptake mechanisms (e.g., SORL1, LRP1) which can bias apparent seeding potency; knockdown or matched receptor expression should be considered when comparing mutants in cells SORL1 and seeding.
• Interpreting toxicity requires caution: seeding potency measured biochemically does not always predict cell toxicity or in vivo pathogenicity; multi-level readouts are essential.

Next steps if hits are found

1. For mutants that markedly increase cross-seeding: perform cryo-EM on amplified fibrils or DEER packing analysis to define the new core and stacking registry and compare to disease cores (e.g., AD PHF folds) DEER fibril packing.
2. Test cross-seeding in primary neurons or organoids with matched uptake receptor levels and assay spread and toxicity over weeks.
3. Consider co-incubation cross-seeding experiments with alpha-synuclein or TDP-43 if mixed pathology is a concern, because cross-talk can modify seeding outcomes (see cross-seeding literature) Tau alpha-synuclein cross-seeding paper.

Concluding recommendation

Run an initial 12-variant focused screen using matched monomer stocks and a seed panel (recombinant fibrils, brain-amplified seeds, sonicated vs non-sonicated). Use ThT kinetics plus the capture and seeded cell aggregation assays for a robust primary screen. Prioritize structural follow-up (DEER/cryo-EM) and primary neuron toxicity only for reproducible, multi-assay hits. This pipeline minimizes false positives driven by seed preparation artifacts and distinguishes changes in seeding potency from changes in templating specificity — the key difference for cross-seeding biology.

Useful immediate actions (one-click)

Run deeper bioinformatics or lab-automation support

Selected references (for every major claim above)

• Two tau seeding assays
• Oligomers drive seeding
• ISAD1 PHF6 inhibition
• SORL1 mediates tau seeding
• Serial amplification and structural validation
• DEER fibril packing method

Confidence note

Confidence in the pipeline approach is moderate to high based on prior use of these orthogonal assays and structural validation studies; final conclusions about specific mutants require the experimental steps above because in vitro conditions and seed composition critically shape outcomes. Key unknowns that would change interpretation: discovery that 353-369 mutations alter receptor-mediated uptake rather than templating, or that identified seeding differences are driven solely by altered oligomerization kinetics rather than stable templating differences.

What would disprove an observed mutant effect

• Reproducible seeding differences that disappear after controlling for seed oligomer content and uptake receptor expression implies the mutation affects oligomerization or uptake rather than templating specificity.
• Identical protease footprint and packing (DEER/cryo-EM) for WT and mutant-seeded assemblies despite apparent kinetic differences would shift interpretation toward assembly kinetics rather than a new structural strain.

Unlimited Evidence-Based Answers